On this page
- ADARx Pharmaceuticals, Inc. IPO
- Bend NovaTech Group Ltd IPO
- Electra Therapeutics, Inc. IPO
- Encore Medical, Inc. IPO
- First Breach, Inc. IPO
- LiPower New Energy Holdings Ltd IPO
- MapLight Therapeutics, Inc. IPO
- Oura Inc. IPO
- Spinnova Plc IPO
- VenHub Global, Inc. IPO
- Wella Co IPO
ADARx Pharmaceuticals, Inc. IPO
ADARx Pharmaceuticals, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-09-04. It has amended it 2 times. It filed its final prospectus on 2026-09-28, at a public offering price of $17.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 16, 2026 | Stake report, Schedule 13G, by Yi Shi | 11.1% of the class | 5%+ stakes | Source |
| October 5, 2026 | Stake report, Schedule 13D, by SR One Capital Management, LLC | 9.3% of the class | 5%+ stakes | Source |
| October 2, 2026 | Stake report, Schedule 13D, by ORBIMED ADVISORS LLC | 14% of the class | 5%+ stakes | Source |
| October 1, 2026 | Stake report, Schedule 13G, by BCLS Fund III Investments, LP | 6.3% of the class | 5%+ stakes | Source |
Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “ADRX.”From the 424B4 filed 2026-09-28
This is an initial public offering of shares of common stock of ADARx Pharmaceuticals, Inc. We are offering 26,250,000 shares of our common stock to be sold in this offering.From the 424B4 filed 2026-09-28
The initial public offering price is $17.00 per share.From the 424B4 filed 2026-09-28
We intend to use the net proceeds from this offering and concurrent private placement, together with our existing cash, cash equivalents and short-term investments, as follows:From the 424B4 filed 2026-09-28
For the years ended December 31, 2024 and 2025, our net losses were $46.4 million and $73.1 million, respectively.From the S-1/A filed 2026-09-21
Bend NovaTech Group Ltd IPO
Bend NovaTech Group Ltd filed a Form F-1 registration statement for an initial public offering on 2025-08-08. It has amended it 3 times. It asked for the registration statement to be withdrawn on 2026-09-01. Each fact below is quoted from the filing named with it.
We have applied to list our Ordinary Shares on the Nasdaq Capital Market under the symbol “BENN” This offering is contingent on the listing of our Ordinary Shares on the Nasdaq Capital Market.From the F-1/A filed 2025-10-22
We are offering 1,250,000 Ordinary Shares and anticipate that the initial public offering price will be between $4.00 and $6.00 per share.From the F-1/A filed 2025-10-22
We are offering 1,250,000 Ordinary Shares and anticipate that the initial public offering price will be between $4.00 and $6.00 per share.From the F-1/A filed 2025-10-22
We plan to use the net proceeds of this offering for (i) enhancement of our production capacity;From the F-1/A filed 2025-10-22
For the fiscal years ended December 31, 2023 and 2024, and the six months ended June 30, 2025, we recorded revenue of $6.2 million, $13.2 million, and $6.4 million, respectively.From the F-1/A filed 2025-10-22
For the fiscal years ended December 31, 2023 we recorded net loss of $0.5 million.From the F-1/A filed 2025-10-22
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Bend NovaTech Group Limited (the “Company”) hereby respectfully requests that the U.S. Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Company’s Registration Statement on Form F-1 (File No. 333-289451) initially filed with the Commission on August 8, 2025, together with all exhibits and amendments thereto (collectively, the “Registration Statement”).From the RW filed 2026-09-01
| Filed | What it is | Filing |
|---|---|---|
| 2025-08-08 | Registration statement filed (foreign issuer) | F-1 |
| 2025-09-02 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-11 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-10-22 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-09-01 | Request to withdraw a registration (Form F-1) | RW |
Electra Therapeutics, Inc. IPO
Electra Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-08-28. It has amended it 1 time. It filed its final prospectus on 2026-09-18, at a public offering price of $15.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 29, 2026 | Stake report, Schedule 13G, by Dr. Beth C. Seidenberg | 10.1% of the class | 5%+ stakes | Source |
| September 28, 2026 | Stake report, Schedule 13G, by LSP 7 Cooperatief U.A. | 6% of the class | 5%+ stakes | Source |
| September 28, 2026 | Stake report, Schedule 13G, by Redmile Group, LLC | 8.7% of the class | 5%+ stakes | Source |
| September 25, 2026 | Stake report, Schedule 13D, by ORBIMED ADVISORS LLC | 11% of the class | 5%+ stakes | Source |
| October 30, 2025 | Form D, private offering | $134.19M sold | Form D page | Source |
Our common stock has been approved for listing on the Nasdaq Global Select Market (Nasdaq) under the symbol “ETRA.”From the 424B4 filed 2026-09-18
We are offering 23,333,334 shares of our common stock.From the 424B4 filed 2026-09-18
The initial public offering price is $15.00 per share of our common stock.From the 424B4 filed 2026-09-18
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, (i) to advance the development of ipsoprubart in sHLH through our ongoing Phase 2/3 global registrational trial topline results and to support BLA submission and commercial readiness activities, (ii) to advance the development of ipsoprubart in T/NK cell malignancies through our ongoing Phase 1 clinical trial, (iii) to advance the development of ELA822 through our ongoing Phase 1 clinical trial in healthy volunteers and initiation of a planned Phase 1/2 clinical trial in patients with T cell-mediated immune disorders, and (iv) for other research and…From the 424B4 filed 2026-09-18
For the years ended December 31, 2024 and 2025, we reported a net loss of $24.8 million and $62.0 million, respectively.From the S-1/A filed 2026-09-14
Encore Medical, Inc. IPO
Encore Medical, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-09-15. It has amended it 8 times. As of its latest filing, on 2026-09-28, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have applied for listing of our common stock on the NYSE American Market (NYSE American) under the symbol “EMI” and the closing of this offering is contingent on such listing.From the S-1/A filed 2026-09-28
This is the initial public offering of common stock of Encore Medical, Inc. We are selling 3,000,000 shares of our common stock.From the S-1/A filed 2026-09-28
We intend to use the net proceeds from this offering primarily to fund our clinical trials, particularly for stroke and migraine indications.From the S-1/A filed 2026-09-28
We had a net loss of $928,088 for the year ended December 31, 2025, and a net loss of $278,915 for the three months ended March 31, 2026.From the S-1/A filed 2026-07-15
| Filed | What it is | Filing |
|---|---|---|
| 2025-09-15 | Registration statement filed | S-1 |
| 2025-12-30 | Registration statement amended | S-1/A |
| 2026-03-03 | Registration statement amended | S-1/A |
| 2026-03-24 | Registration statement amended | S-1/A |
| 2026-04-06 | Registration statement amended | S-1/A |
| 2026-07-01 | Registration statement amended | S-1/A |
| 2026-07-15 | Registration statement amended | S-1/A |
| 2026-08-10 | Registration statement amended | S-1/A |
| 2026-09-28 | Registration statement amended | S-1/A |
First Breach, Inc. IPO
First Breach, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-04-30. It has amended it 4 times. It filed its final prospectus on 2026-08-31. Each fact below is quoted from the filing named with it.
Our common stock is listed on The Nasdaq Capital Market under the symbol “FBDT”.From the S-1 filed 2026-09-02
We intend to use the net proceeds from the April 2026 Note Financing for general corporate purposes and general working capital requirements, including the payment of transaction-related fees and expenses.From the S-1 filed 2026-09-02
Revenue increased by $250,452 for the six months ended June 30, 2026, compared to the six months ended June 30, 2025.From the S-1 filed 2026-09-02
The net loss associated with liquidation of raw materials for the six months ended June 30, 2026 and 2025 was $0 and $684,960, respectively, attributable to the liquidation of certain raw material inventory outside the normal course of operations to support operating cash flow and working capital management, which resulted in proceeds below the inventory’s carrying value.From the S-1 filed 2026-09-02
| Filed | What it is | Filing |
|---|---|---|
| 2026-04-30 | Registration statement filed | S-1 |
| 2026-05-27 | Registration statement amended | S-1/A |
| 2026-06-12 | Registration statement amended | S-1/A |
| 2026-08-03 | Registration statement amended | S-1/A |
| 2026-08-07 | Registration statement amended | S-1/A |
| 2026-08-20 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-08-31 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-09-02 | Registration statement filed | S-1 |
LiPower New Energy Holdings Ltd IPO
LiPower New Energy Holdings Ltd filed a Form F-1 registration statement for an initial public offering on 2026-09-02. It has amended it 1 time. As of its latest filing, on 2026-09-03, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “LPNE”.From the F-1/A filed 2026-09-03
We are offering 5,000,000 shares at an assumed offering price of US$5 or US$6 per ordinary share.From the F-1/A filed 2026-09-03
MapLight Therapeutics, Inc. IPO
MapLight Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-09-19. It has amended it 2 times. As of its latest filing, on 2026-09-18, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 20, 2026 | Stake report, Schedule 13G, by Nan Fung Group Holdings Limited | 5.5% of the class | 5%+ stakes | Source |
| August 18, 2026 | Stake report, Schedule 13D/A, by Catalyst4, Inc. | 49.9% of the class | 5%+ stakes | Source |
| August 3, 2026 | Stake report, Schedule 13D/A, by Catalyst4, Inc. | 47.9% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13D/A, by Novo Holdings A/S | 4.9% of the class | 5%+ stakes | Source |
| June 18, 2026 | Leadership change: Jonathan Gillis appointed, Chief Financial Officer | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 7.4% of the class | 5%+ stakes | Source |
| April 29, 2026 | Leadership change: Robert Malenka departs | — | Leadership changes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 6.2% of the class | 5%+ stakes | Source |
| November 20, 2025 | Stake report, Schedule 13D, by Catalyst4, Inc. | 45.1% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13D, by Novo Holdings A/S | 8.4% of the class | 5%+ stakes | Source |
| July 28, 2025 | Form D, private offering | $188.19M sold | Form D page | Source |
Our common stock is listed on the Nasdaq Global Select Market under the symbol “MPLT.” On September 17, 2026, the last reported sale price for our common stock on the Nasdaq Global Select Market was $11.32 per share.From the S-1/A filed 2026-09-18
We are offering 14,750,000 shares of our common stock.From the S-1/A filed 2025-10-06
We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash, cash equivalents and short-term investments, to advance the clinical development of our current programs, to fund research and development activities for additional programs, and for working capital and other general corporate purposes.From the S-1/A filed 2025-10-06
For the years ended December 31, 2024 and 2023 and for the six months ended June 30, 2025, our net losses were $77.6 million, $55.7 million and $52.2 million, respectively.From the S-1/A filed 2025-10-06
Oura Inc. IPO
Oura Inc. filed a Form S-1 registration statement for an initial public offering on 2026-09-03. It has amended it 1 time. As of its latest filing, on 2026-09-21, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have applied to list our common stock on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “OURA.”From the S-1/A filed 2026-09-21
This is the initial public offering of shares of common stock of Oura Inc. We are offering 13,500,000 shares of our common stock, and the selling stockholders identified in this prospectus are offering 36,500,000 shares of our common stock.From the S-1/A filed 2026-09-21
We intend to use the net proceeds from this offering for general corporate purposes, including technology development, working capital, operating expenses, and capital expenditures.From the S-1 filed 2026-09-03
Our revenue was $1,214.5 million and $697.6 million during the nine months ended June 30, 2026 and 2025, respectively, representing 74% year-over-year growth.From the S-1/A filed 2026-09-21
During the nine months ended June 30, 2026 and 2025, we delivered gross margins of 55% and 51%, generated net income of $60.8 million and $1.6 million, and generated Adjusted EBITDA of $106.7 million and $83.5 million, respectively.From the S-1/A filed 2026-09-21
Spinnova Plc IPO
Spinnova Plc filed a Form F-1 registration statement for an initial public offering on 2026-08-27. It has amended it 1 time. As of its latest filing, on 2026-09-23, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have applied to list the ADSs on The Nasdaq Stock Market LLC, or the Nasdaq, under the symbol “SPNV.” Our shares are listed on the Finnish Stock Exchange under the symbol “SPINN.” On , 2026, the last per share closing price of our shares on the Finnish Stock Exchange was .From the F-1/A filed 2026-09-23
We intend to use the net proceeds from this offering to support the ramp-up of our Eteläportti demonstration facility, advance commercialization of our technology, and for working capital and general corporate purposes.From the F-1/A filed 2026-09-23
VenHub Global, Inc. IPO
VenHub Global, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-10-03. It has amended it 3 times. As of its latest filing, on 2026-09-10, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 3, 2025 | Crowdfunding filing, Form C-U | $10K target | Crowdfunding | Source |
| April 29, 2025 | Crowdfunding filing, Form C/A | $10K target | Crowdfunding | Source |
| April 28, 2025 | Crowdfunding filing, Form C-AR | — | Crowdfunding | Source |
Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “VHUB.” On September 10, 2026, the closing sale price of our common stock as reported on Nasdaq was $0.849.From the S-1/A filed 2026-09-10
There was $864,450 of revenue and $583,760 in cost of goods sold for the year ended December 31, 2025. $750,000 of the revenue was related to our store sales and $114,450 relating to our store product revenue from our Company owned stores.From the S-1/A filed 2026-04-09
During the years ended December 31, 2025 and 2024, we incurred net losses of approximately $62.4 million and $9.4 million, respectively.From the S-1/A filed 2026-09-10
| Filed | What it is | Filing |
|---|---|---|
| 2025-10-03 | Registration statement filed | S-1 |
| 2026-03-24 | Registration statement filed | S-1 |
| 2026-04-09 | Registration statement amended | S-1/A |
| 2026-06-22 | Registration statement filed | S-1 |
| 2026-07-01 | Registration statement amended | S-1/A |
| 2026-09-03 | Registration statement filed | S-1 |
| 2026-09-10 | Registration statement amended | S-1/A |
Wella Co IPO
Wella Co filed a Form S-1 registration statement for an initial public offering on 2026-08-31. It has amended it 1 time. As of its latest filing, on 2026-09-23, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have applied to list our common stock on the New York Stock Exchange, or the NYSE, under the symbol “WELA.”From the S-1/A filed 2026-09-23
Net revenue increased from $2.6 billion in 2024 to $2.9 billion in 2026.From the S-1/A filed 2026-09-23
Increased net income from a net loss of $115 million in fiscal 2024 to net income of $62 million in fiscal 2026;From the S-1/A filed 2026-09-23
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.